- Yale UrologyVA Connecticut Healthcare950 Campbell AvenueWest Haven, CT 06516
- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519
Preston C. Sprenkle, MD
Biography
Preston C. Sprenkle, MD, specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma—a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.
Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.
“Skilled and experienced radiologists are rare for this relatively new technique,” Dr. Sprenkle explains. “At Yale, we are fortunate to have some of the world leaders in prostate MRI.”
Dr. Sprenkle is also a pioneer in “focal therapy,” which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects—such as erectile dysfunction and incontinence—that may follow the removal of the whole prostate.
“Exciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,” Dr. Sprenkle says. “Developing ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.”
Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. “I want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.”
Titles
- Associate Professor of Urology
- Director, Urology Research Fellowship, Urology
- Co-Chair, Cancer Liaison Committee, Oncology, VA Connecticut Healthcare System
- Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection, National Comprehensive Cancer Network (NCCN)
- Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology, VA Connecticut Healthcare System
Education & Training
- Non Degree ProgramYale School of Management, Emerging Leaders Program (2018)
- FellowshipMemorial Sloan Kettering Cancer Center (2011)
- ResidencyNew York Presbyterian Hospital (2009)
- InternshipNew York Presbyterian Hospital (2005)
- MDColumbia University (2004)
- BAStanford University, Human Biology (1998)
Languages Spoken
- English
- Español (Spanish)
Additional Information
- 2021 Thesis Reviewer, PA Master Thesis Committee, Yale School of Medicine: (2021)
- Mentor Appreciation Award: Interprofessional Longitudinal Clinical Experience (2017), (2018), (2019), (2020)
- Best Poster Podium Presentation: Young Urologic Oncologist dinner, Society Of Urologic Oncology Annual Meeting (2009)
- Finalist - NY section AUA Valentine Essay Contest: NY Academy of Medicine (2009)
- Finalist - NY section AUA Valentine Essay Contest: NY Academy of Medicine (2007)
- First Prize - NY section AUA Valentine Essay Contest: NY Academy of Medicine (2006)
- Arnold P. Gold Humanism in Medicine Honors Society: (2004)
- Alpha Omega Alpha Medical School Honors Society: (2004)
- Outstanding Member of Stanford Community: Stanford University (1998)
- Member, Board of Directors: Stanford University Alumni Association (1997)
- ADMETECH Global Summit (2024): Prostate cancer detection and Screening Section Moderator
- National Surgery Office (2024 - 2027): Chair
- Johnson & Johnson (2024 - Present): Advisor
- Yale Urology Bulldog Debate CME Event - Oncology Section (2023): Designed oncology curriculum for CME Event and recruited participating lecturers/debaters.
- PhD candidate Thesis examiner - Joanna Chen (2023 - Present): Thesis Reviewer
- Telix Pharmaceuticals (2022 - Present): Advisor
- Profound Medical (2022 - Present): Board Member
- National Surgery Office (2021 - 2024): Member
- YNHH Robotic Surgery Committee (2021 - Present): Member
- NCCN Prostate Cancer Early Detection Guideline Panel (2021 - Present): Vice Chair
- Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024 PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.
- Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.
- Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.
- Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.
- Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.
- Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.
- Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle P, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy. Urology 2024, 193: 87-94. PMID: 39019332, DOI: 10.1016/j.urology.2024.07.014.
- Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.
- Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.
- Webb L, Diaz G, Velasquez E, Goberdhan S, Khajir G, Sundaresan V, Leapman M, Sprenkle P. MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSY. Journal Of Urology 2024, 211: e315. DOI: 10.1097/01.ju.0001008716.22569.77.12.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.
- Shumaker L, Fang A, Kaneko M, Ramacciotti L, Prakash N, Das A, Patel H, Khajir G, Fan R, Wang S, Pineault K, Sidana A, Gupta G, Filson C, Wysock J, Siddiqui M, Sonn G, Sprenkle P, Ross A, Jarrard D, Punnen S, Abreu A, Rais-Bahrami S. MP19-16 INCORPORATING PROSTATE MRI IMAGING CHARACTERISTICS TO IMPROVE PROSTATE CANCER DIAGNOSIS AND RISK STRATIFICATION: AN ANALYSIS AND NOMOGRAM DERIVED FROM A 9,536 PATIENT, MULTI-INSTITUTIONAL COHORT. Journal Of Urology 2024, 211: e316. DOI: 10.1097/01.ju.0001008716.22569.77.16.
- Diaz G, Webb L, Khajir G, Sprenkle P. MP19-09 PREDICTORS OF A POSITIVE BIOPSY FOLLOWING A PIRADS 3 FINDING ON MRI. Journal Of Urology 2024, 211: e313. DOI: 10.1097/01.ju.0001008716.22569.77.09.
- Webb L, Diaz G, Rahman S, Khajir G, Sprenkle P. MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE? Journal Of Urology 2024, 211: e504. DOI: 10.1097/01.ju.0001008936.35187.0b.04.
- Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.
- Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Brito J, Renzulli J, Sprenkle P, Michael M. A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study. European Urology 2024, 85: s1101. DOI: 10.1016/s0302-2838(24)00884-4.
- Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
- Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
- Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.
- Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.
- Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.
- Esmaili R, Khajir G, Leapman M, Sprenkle P, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Journal Of Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.
- Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Sprenkle P, Ross A. MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET. Journal Of Urology 2023, 209: e212. DOI: 10.1097/ju.0000000000003237.02.
- Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Ross A, Sprenkle P. MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE. Journal Of Urology 2023, 209: e216. DOI: 10.1097/ju.0000000000003237.09.
- Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.
- Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. PD20-07 ASSOCIATIONS BETWEEN PATIENT SOCIODEMOGRAPHIC FACTORS AND RISK-APPROPRIATE PROSTATE CANCER MANAGEMENT. Journal Of Urology 2023, 209: e586. DOI: 10.1097/ju.0000000000003286.07.
- Smani S, Novosel M, Marks V, Jeong F, Sprenkle P, Leapman M. MP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFE. Journal Of Urology 2023, 209: e1079. DOI: 10.1097/ju.0000000000003349.01.
- Khan A, Choksi A, Rahman S, Press B, Jalfon M, Gardezi M, Jones T, Hayden C, Ghiraldi E, Siev M, Lacy G, Sprenkle P, Kellner D. MP59-12 CAN ANATOMICAL MEASUREMENTS ON PREOPERATIVE PELVIC MAGNETIC RESONANCE IMAGING PREDICT POSTOPERATIVE URINARY INCONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE? Journal Of Urology 2023, 209: e812. DOI: 10.1097/ju.0000000000003312.12.
- Moses K, Sprenkle P, Bahler C, Box G, Carlsson S, Catalona W, Dahl D, Dall'Era M, Davis J, Drake B, Epstein J, Etzioni R, Farrington T, Garraway I, Jarrard D, Kauffman E, Kaye D, Kibel A, LaGrange C, Maroni P, Ponsky L, Reys B, Salami S, Sanchez A, Seibert T, Shaneyfelt T, Smaldone M, Sonn G, Tyson M, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi R, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 236-246. PMID: 36898362, DOI: 10.6004/jnccn.2023.0014.
- Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Journal Of Clinical Oncology 2023, 41: 307-307. DOI: 10.1200/jco.2023.41.6_suppl.307.
- Smani S, Novosel M, Jeong F, Marks V, Sprenkle P, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.
- Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2023, 0: 0-0. DOI: 10.21037/tcr-24-245.
- Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.
- Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana‐Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais‐Bahrami S. Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions. Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.
- Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.
- Khajir G, Press B, Sprenkle P, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES. Journal Of Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.
- Khajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Journal Of Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.
- Fang A, Shumaker L, Martin K, Onah O, Jackson J, Khajir G, Fan R, Soodana-Prakash N, Patel H, Vourganti S, Filson C, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2022, 207: e959. DOI: 10.1097/ju.0000000000002637.01.
- Leapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING. Journal Of Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
- Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.
- Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- Fang A, Shumaker L, Khajir G, Fan R, Soodana-Prakash N, Patel H, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2021, 206: e78-e78. DOI: 10.1097/ju.0000000000001972.05.
- Syed J, Sprenkle P. Benign and Malignant Diseases of the Prostate. 2020, 651-682. DOI: 10.1007/978-3-319-47771-8_79.
- Abello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy. European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
- Sprenkle* P, Carroll P, Probst S, Gorin M, Rowe S, Pienta K, Pouliot F, Patnaik A, Preston M, Alva A, Siegel B, Morris M. PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000917.05.
- Abello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY. Journal Of Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.
- Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.
- Syed J, Sprenkle P. Benign and Malignant Diseases of the Prostate. 2019, 1-32. DOI: 10.1007/978-3-319-20317-1_79-1.
- Yang D, Yu J, An Y, Sprenkle P, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.
- Martin D, Ghabili* K, Levi A, Humphrey P, Schulam P, Sprenkle P. PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555367.28091.c8.
- Abello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
- Javier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
- Wang N, Fan R, Sprenkle P, Sonn G. MP77-19 CLINICAL TOOL PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN. Journal Of Urology 2018, 199: e1035. DOI: 10.1016/j.juro.2018.02.2607.
- Leung C, Syed J, Pan S, Neville T, Sprenkle P. MP01-20 THE LEARNING CURVE FOR MULTI-PARAMETRIC MRI/US FUSION GUIDED PROSTATE BIOPSY: A SINGLE CENTER EXPERIENCE. Journal Of Urology 2018, 199: e11. DOI: 10.1016/j.juro.2018.02.126.
- Amirkhiz K, Suarez-Sarmiento A, Nguyen K, Hsiang W, Amalraj S, Syed J, Leapman M, Schulam P, Sprenkle P. MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e707-e708. DOI: 10.1016/j.juro.2018.02.1681.
- Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Journal Of Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.
- Hsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE. Journal Of Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.
- Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.
- Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.
- Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.
- Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.
- Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, Sprenkle P. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.
- Nguyen K, Nawaf C, Levi A, Huber S, Lu A, Say R, Sprenkle P. Bacillus Calmette–Guérin therapy-induced granulomatous prostatitis on multiparametric magnetic resonance imaging: a case report. Journal Of Clinical Urology 2016, 10: 280-282. DOI: 10.1177/2051415816651561.
- Lu A, Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS? Journal Of Urology 2016, 195: e393. DOI: 10.1016/j.juro.2016.02.1137.
- Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. MP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCER. Journal Of Urology 2016, 195: e158. DOI: 10.1016/j.juro.2016.02.2541.
- Ehrenberg H, Cornfeld D, Nawaf C, Sprenkle P, Duncan J. Decision forests for learning prostate cancer probability maps from multiparametric MRI. Proceedings Of SPIE--the International Society For Optical Engineering 2016, 9785: 97851j-97851j-14. DOI: 10.1117/12.2216904.
- Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.
- Nawaf C, Rosoff J, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.
- Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.
- Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Humphrey P, Levi A, Sprenkle P. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.
- Kardos S, Pan S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE. Journal Of Urology 2015, 193: e179. DOI: 10.1016/j.juro.2015.02.850.
- Karnes R, Loeb S, Sprenkle P, Morrell C, MacKintosh F, Rawson L, Neville T. MP86-08 CONFIRMATION: ANALYSIS OF PSA TRENDS HELPS IDENTIFY DEADLY PROSTATE CANCERS PRIOR TO BIOPSY. Journal Of Urology 2015, 193: e1078-e1079. DOI: 10.1016/j.juro.2015.02.1917.
- Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.
- Sprenkle P, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, Goluboff E, Benson M, Rutman M. Exploring medical student education initiatives: does the management of urologic conditions improve with a formal urology clinical clerkship? Journal Of Medicine And The Person 2011, 9: 116-122. DOI: 10.1007/s12682-011-0101-y.
- Sprenkle P, Sankin A, Savage C, Musser J, Touijer K, Russo P, Coleman J. 1269 OUTCOMES FOLLOWING RENAL SURGERY IN HIGH-RISK PATIENTS: A NON-RANDOMIZED COMPARISON OF OPEN AND MINIMALLY INVASIVE SURGICAL APPROACHES. Journal Of Urology 2011, 185: e507. DOI: 10.1016/j.juro.2011.02.954.
- Hruby G, Sprenkle P, Lehman D, Durak E, Marruffo F, Mirabile G, McKiernan J, Gupta M, Landman J. COMPARISON OF COMPLETE INTRACORPOREAL CONSTRUCTION OF AN ILEUM NEOBLADDER UTILIZING STANDARD SUTURED TECHNIQUES AND NOVEL TECHNOLOGIES. Journal Of Urology 2008, 179: 248. DOI: 10.1016/s0022-5347(08)60716-8.
- Sprenkle P, Mirabile G, Hruby G, Phillips C, Xavier K, Gupta M, Landman J. THE EFFECT OF ARGON GAS PRESSURE ON ICE BALL SIZE AND RATE OF FORMATION. Journal Of Urology 2008, 179: 243-244. DOI: 10.1016/s0022-5347(08)60703-x.
- Pierorazio P, Lambert S, Matsukhani M, Sprenkle P, McCann T, Katz A, Olsson C, Benson M, McKiernan J. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. BJU International 2007, 0: 070907021207002-???. DOI: 10.1111/j.1464-410x.2007.07115.x.
- Sprenkle P, Lowe F. Benign prostate hyperplasia in the older male. Aging Health 2007, 3: 177-189. DOI: 10.2217/1745509x.3.2.177.
- Lambert S, Batourina E, Tsai S, Viana R, Sprenkle P, Dutta S, Hensle T, Mendelsohn C. 578: Distal Ureteral Morphogenesis Depends on Apoptosis Induced by Signals from the Urogenital Sinus: A New Model of Ureteral Maturation. Journal Of Urology 2006, 175: 187-188. DOI: 10.1016/s0022-5347(18)32824-6.
- Sprenkle P, Batourina E, Tsai S, Lambert S, Paragas N, Glassberg K, Hensle T, Mendelsohn C. 1717: The Bladder Trigone is not a Wolffian Duct Remnant. Journal Of Urology 2004, 171: 454. DOI: 10.1016/s0022-5347(18)38909-2.
- Yale UrologyVA Connecticut Healthcare950 Campbell AvenueWest Haven, CT 06516
- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519
Biography
Preston C. Sprenkle, MD, specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma—a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.
Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.
“Skilled and experienced radiologists are rare for this relatively new technique,” Dr. Sprenkle explains. “At Yale, we are fortunate to have some of the world leaders in prostate MRI.”
Dr. Sprenkle is also a pioneer in “focal therapy,” which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects—such as erectile dysfunction and incontinence—that may follow the removal of the whole prostate.
“Exciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,” Dr. Sprenkle says. “Developing ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.”
Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. “I want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.”
Titles
- Associate Professor of Urology
- Director, Urology Research Fellowship, Urology
- Co-Chair, Cancer Liaison Committee, Oncology, VA Connecticut Healthcare System
- Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection, National Comprehensive Cancer Network (NCCN)
- Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology, VA Connecticut Healthcare System
Education & Training
- Non Degree ProgramYale School of Management, Emerging Leaders Program (2018)
- FellowshipMemorial Sloan Kettering Cancer Center (2011)
- ResidencyNew York Presbyterian Hospital (2009)
- InternshipNew York Presbyterian Hospital (2005)
- MDColumbia University (2004)
- BAStanford University, Human Biology (1998)
Languages Spoken
- English
- Español (Spanish)
Additional Information
- 2021 Thesis Reviewer, PA Master Thesis Committee, Yale School of Medicine: (2021)
- Mentor Appreciation Award: Interprofessional Longitudinal Clinical Experience (2017), (2018), (2019), (2020)
- Best Poster Podium Presentation: Young Urologic Oncologist dinner, Society Of Urologic Oncology Annual Meeting (2009)
- Finalist - NY section AUA Valentine Essay Contest: NY Academy of Medicine (2009)
- Finalist - NY section AUA Valentine Essay Contest: NY Academy of Medicine (2007)
- First Prize - NY section AUA Valentine Essay Contest: NY Academy of Medicine (2006)
- Arnold P. Gold Humanism in Medicine Honors Society: (2004)
- Alpha Omega Alpha Medical School Honors Society: (2004)
- Outstanding Member of Stanford Community: Stanford University (1998)
- Member, Board of Directors: Stanford University Alumni Association (1997)
- ADMETECH Global Summit (2024): Prostate cancer detection and Screening Section Moderator
- National Surgery Office (2024 - 2027): Chair
- Johnson & Johnson (2024 - Present): Advisor
- Yale Urology Bulldog Debate CME Event - Oncology Section (2023): Designed oncology curriculum for CME Event and recruited participating lecturers/debaters.
- PhD candidate Thesis examiner - Joanna Chen (2023 - Present): Thesis Reviewer
- Telix Pharmaceuticals (2022 - Present): Advisor
- Profound Medical (2022 - Present): Board Member
- National Surgery Office (2021 - 2024): Member
- YNHH Robotic Surgery Committee (2021 - Present): Member
- NCCN Prostate Cancer Early Detection Guideline Panel (2021 - Present): Vice Chair
- Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024 PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.
- Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.
- Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.
- Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.
- Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.
- Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.
- Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle P, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy. Urology 2024, 193: 87-94. PMID: 39019332, DOI: 10.1016/j.urology.2024.07.014.
- Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.
- Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.
- Webb L, Diaz G, Velasquez E, Goberdhan S, Khajir G, Sundaresan V, Leapman M, Sprenkle P. MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSY. Journal Of Urology 2024, 211: e315. DOI: 10.1097/01.ju.0001008716.22569.77.12.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.
- Shumaker L, Fang A, Kaneko M, Ramacciotti L, Prakash N, Das A, Patel H, Khajir G, Fan R, Wang S, Pineault K, Sidana A, Gupta G, Filson C, Wysock J, Siddiqui M, Sonn G, Sprenkle P, Ross A, Jarrard D, Punnen S, Abreu A, Rais-Bahrami S. MP19-16 INCORPORATING PROSTATE MRI IMAGING CHARACTERISTICS TO IMPROVE PROSTATE CANCER DIAGNOSIS AND RISK STRATIFICATION: AN ANALYSIS AND NOMOGRAM DERIVED FROM A 9,536 PATIENT, MULTI-INSTITUTIONAL COHORT. Journal Of Urology 2024, 211: e316. DOI: 10.1097/01.ju.0001008716.22569.77.16.
- Diaz G, Webb L, Khajir G, Sprenkle P. MP19-09 PREDICTORS OF A POSITIVE BIOPSY FOLLOWING A PIRADS 3 FINDING ON MRI. Journal Of Urology 2024, 211: e313. DOI: 10.1097/01.ju.0001008716.22569.77.09.
- Webb L, Diaz G, Rahman S, Khajir G, Sprenkle P. MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE? Journal Of Urology 2024, 211: e504. DOI: 10.1097/01.ju.0001008936.35187.0b.04.
- Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.
- Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Brito J, Renzulli J, Sprenkle P, Michael M. A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study. European Urology 2024, 85: s1101. DOI: 10.1016/s0302-2838(24)00884-4.
- Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
- Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
- Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.
- Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.
- Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.
- Esmaili R, Khajir G, Leapman M, Sprenkle P, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Journal Of Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.
- Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Sprenkle P, Ross A. MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET. Journal Of Urology 2023, 209: e212. DOI: 10.1097/ju.0000000000003237.02.
- Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Ross A, Sprenkle P. MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE. Journal Of Urology 2023, 209: e216. DOI: 10.1097/ju.0000000000003237.09.
- Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.
- Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. PD20-07 ASSOCIATIONS BETWEEN PATIENT SOCIODEMOGRAPHIC FACTORS AND RISK-APPROPRIATE PROSTATE CANCER MANAGEMENT. Journal Of Urology 2023, 209: e586. DOI: 10.1097/ju.0000000000003286.07.
- Smani S, Novosel M, Marks V, Jeong F, Sprenkle P, Leapman M. MP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFE. Journal Of Urology 2023, 209: e1079. DOI: 10.1097/ju.0000000000003349.01.
- Khan A, Choksi A, Rahman S, Press B, Jalfon M, Gardezi M, Jones T, Hayden C, Ghiraldi E, Siev M, Lacy G, Sprenkle P, Kellner D. MP59-12 CAN ANATOMICAL MEASUREMENTS ON PREOPERATIVE PELVIC MAGNETIC RESONANCE IMAGING PREDICT POSTOPERATIVE URINARY INCONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE? Journal Of Urology 2023, 209: e812. DOI: 10.1097/ju.0000000000003312.12.
- Moses K, Sprenkle P, Bahler C, Box G, Carlsson S, Catalona W, Dahl D, Dall'Era M, Davis J, Drake B, Epstein J, Etzioni R, Farrington T, Garraway I, Jarrard D, Kauffman E, Kaye D, Kibel A, LaGrange C, Maroni P, Ponsky L, Reys B, Salami S, Sanchez A, Seibert T, Shaneyfelt T, Smaldone M, Sonn G, Tyson M, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi R, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 236-246. PMID: 36898362, DOI: 10.6004/jnccn.2023.0014.
- Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Journal Of Clinical Oncology 2023, 41: 307-307. DOI: 10.1200/jco.2023.41.6_suppl.307.
- Smani S, Novosel M, Jeong F, Marks V, Sprenkle P, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.
- Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2023, 0: 0-0. DOI: 10.21037/tcr-24-245.
- Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.
- Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana‐Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais‐Bahrami S. Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions. Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.
- Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.
- Khajir G, Press B, Sprenkle P, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES. Journal Of Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.
- Khajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Journal Of Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.
- Fang A, Shumaker L, Martin K, Onah O, Jackson J, Khajir G, Fan R, Soodana-Prakash N, Patel H, Vourganti S, Filson C, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2022, 207: e959. DOI: 10.1097/ju.0000000000002637.01.
- Leapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING. Journal Of Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
- Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.
- Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- Fang A, Shumaker L, Khajir G, Fan R, Soodana-Prakash N, Patel H, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2021, 206: e78-e78. DOI: 10.1097/ju.0000000000001972.05.
- Syed J, Sprenkle P. Benign and Malignant Diseases of the Prostate. 2020, 651-682. DOI: 10.1007/978-3-319-47771-8_79.
- Abello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy. European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
- Sprenkle* P, Carroll P, Probst S, Gorin M, Rowe S, Pienta K, Pouliot F, Patnaik A, Preston M, Alva A, Siegel B, Morris M. PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000917.05.
- Abello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY. Journal Of Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.
- Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.
- Syed J, Sprenkle P. Benign and Malignant Diseases of the Prostate. 2019, 1-32. DOI: 10.1007/978-3-319-20317-1_79-1.
- Yang D, Yu J, An Y, Sprenkle P, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.
- Martin D, Ghabili* K, Levi A, Humphrey P, Schulam P, Sprenkle P. PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555367.28091.c8.
- Abello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
- Javier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
- Wang N, Fan R, Sprenkle P, Sonn G. MP77-19 CLINICAL TOOL PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN. Journal Of Urology 2018, 199: e1035. DOI: 10.1016/j.juro.2018.02.2607.
- Leung C, Syed J, Pan S, Neville T, Sprenkle P. MP01-20 THE LEARNING CURVE FOR MULTI-PARAMETRIC MRI/US FUSION GUIDED PROSTATE BIOPSY: A SINGLE CENTER EXPERIENCE. Journal Of Urology 2018, 199: e11. DOI: 10.1016/j.juro.2018.02.126.
- Amirkhiz K, Suarez-Sarmiento A, Nguyen K, Hsiang W, Amalraj S, Syed J, Leapman M, Schulam P, Sprenkle P. MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e707-e708. DOI: 10.1016/j.juro.2018.02.1681.
- Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Journal Of Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.
- Hsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE. Journal Of Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.
- Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.
- Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.
- Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.
- Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.
- Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, Sprenkle P. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.
- Nguyen K, Nawaf C, Levi A, Huber S, Lu A, Say R, Sprenkle P. Bacillus Calmette–Guérin therapy-induced granulomatous prostatitis on multiparametric magnetic resonance imaging: a case report. Journal Of Clinical Urology 2016, 10: 280-282. DOI: 10.1177/2051415816651561.
- Lu A, Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS? Journal Of Urology 2016, 195: e393. DOI: 10.1016/j.juro.2016.02.1137.
- Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. MP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCER. Journal Of Urology 2016, 195: e158. DOI: 10.1016/j.juro.2016.02.2541.
- Ehrenberg H, Cornfeld D, Nawaf C, Sprenkle P, Duncan J. Decision forests for learning prostate cancer probability maps from multiparametric MRI. Proceedings Of SPIE--the International Society For Optical Engineering 2016, 9785: 97851j-97851j-14. DOI: 10.1117/12.2216904.
- Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.
- Nawaf C, Rosoff J, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.
- Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.
- Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Humphrey P, Levi A, Sprenkle P. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.
- Kardos S, Pan S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE. Journal Of Urology 2015, 193: e179. DOI: 10.1016/j.juro.2015.02.850.
- Karnes R, Loeb S, Sprenkle P, Morrell C, MacKintosh F, Rawson L, Neville T. MP86-08 CONFIRMATION: ANALYSIS OF PSA TRENDS HELPS IDENTIFY DEADLY PROSTATE CANCERS PRIOR TO BIOPSY. Journal Of Urology 2015, 193: e1078-e1079. DOI: 10.1016/j.juro.2015.02.1917.
- Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.
- Sprenkle P, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, Goluboff E, Benson M, Rutman M. Exploring medical student education initiatives: does the management of urologic conditions improve with a formal urology clinical clerkship? Journal Of Medicine And The Person 2011, 9: 116-122. DOI: 10.1007/s12682-011-0101-y.
- Sprenkle P, Sankin A, Savage C, Musser J, Touijer K, Russo P, Coleman J. 1269 OUTCOMES FOLLOWING RENAL SURGERY IN HIGH-RISK PATIENTS: A NON-RANDOMIZED COMPARISON OF OPEN AND MINIMALLY INVASIVE SURGICAL APPROACHES. Journal Of Urology 2011, 185: e507. DOI: 10.1016/j.juro.2011.02.954.
- Hruby G, Sprenkle P, Lehman D, Durak E, Marruffo F, Mirabile G, McKiernan J, Gupta M, Landman J. COMPARISON OF COMPLETE INTRACORPOREAL CONSTRUCTION OF AN ILEUM NEOBLADDER UTILIZING STANDARD SUTURED TECHNIQUES AND NOVEL TECHNOLOGIES. Journal Of Urology 2008, 179: 248. DOI: 10.1016/s0022-5347(08)60716-8.
- Sprenkle P, Mirabile G, Hruby G, Phillips C, Xavier K, Gupta M, Landman J. THE EFFECT OF ARGON GAS PRESSURE ON ICE BALL SIZE AND RATE OF FORMATION. Journal Of Urology 2008, 179: 243-244. DOI: 10.1016/s0022-5347(08)60703-x.
- Pierorazio P, Lambert S, Matsukhani M, Sprenkle P, McCann T, Katz A, Olsson C, Benson M, McKiernan J. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. BJU International 2007, 0: 070907021207002-???. DOI: 10.1111/j.1464-410x.2007.07115.x.
- Sprenkle P, Lowe F. Benign prostate hyperplasia in the older male. Aging Health 2007, 3: 177-189. DOI: 10.2217/1745509x.3.2.177.
- Lambert S, Batourina E, Tsai S, Viana R, Sprenkle P, Dutta S, Hensle T, Mendelsohn C. 578: Distal Ureteral Morphogenesis Depends on Apoptosis Induced by Signals from the Urogenital Sinus: A New Model of Ureteral Maturation. Journal Of Urology 2006, 175: 187-188. DOI: 10.1016/s0022-5347(18)32824-6.
- Sprenkle P, Batourina E, Tsai S, Lambert S, Paragas N, Glassberg K, Hensle T, Mendelsohn C. 1717: The Bladder Trigone is not a Wolffian Duct Remnant. Journal Of Urology 2004, 171: 454. DOI: 10.1016/s0022-5347(18)38909-2.
- Yale UrologyVA Connecticut Healthcare950 Campbell AvenueWest Haven, CT 06516
- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519
- Yale UrologyVA Connecticut Healthcare950 Campbell AvenueWest Haven, CT 06516
- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519